TESTOSTERONE | N022504 | ELI LILLY AND CO
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2017-04-21 | Terminated 2017-07-19 | — | |
| D. Del. | 2017-02-17 | Terminated 2017-05-18 | — | |
Eli Lilly and Company et al v. Lupin Pharmaceuticals, Inc. et al 5 patentsANDA 208061testosterone | E.D. Va. | 2015-07-09 | Terminated 2017-02-15 | — |
| S.D. Ind. | 2013-05-24 | Terminated 2016-09-22 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from K&L Gates LLP FDA-2018-P-2506 · 4 docket documents K&L Gates LLP filed this petition on behalf of an ANDA applicant seeking an FDA determination that AXIRON (testosterone) transdermal metered solution 30mg/1.5mL, approved under NDA N022504 and held by Eli Lilly and Company, was not voluntarily withdrawn for reasons of safety or effectiveness, which | 505(q) | 2018-06-28 | Granted | K&L Gates LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.